When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
A phase 2 trial of Capricor Therapeutics' (NASDAQ:CAPR) COVID-19 treatment CAP-1002 met its primary objective of safety. Although the study was not powered to determine efficacy, overall mortality was 20%. There were six deaths in the placebo group and five in the CAP-1002 group. Patients enrolled in the study were hospitalized with severe symptoms. Check out Capricor's (CAPR) recent Q4 2021 results.